A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors

Inclusion Criteria: * Confirmed diagnosis of an advanced or metastatic solid tumor that is relapsed or refractory following previous therapy, and for which there is no available standard therapy. * Availability of PD-L1 Tumor Proportion Score (TPS) or Combined Positive Score (CPS); OR willingness to submit tumor tissue, if available, for central testing. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. * Age ≥ 18 years at the time of signing the informed consent. * Adequate hepatic function. * Adequate renal function. * Adequate bone marrow function. * Adequate blood clotting function Exclusion Criteria: * Active, untreated brain metastases or leptomeningeal disease requiring immediate local therapy, with some exceptions. * Concurrent malignancy that is progressing or requires active treatment, with some exceptions. * Received prior treatment within 5 half-lives or 4 weeks prior to starting AXN-2510, whichever is shorter (6 weeks for nitrosourea or mitomycin-C). Patients with prostate or breast cancer may continue concurrent hormone therapy. * Current use of immune-suppressive medication at the time of study enrollment, with some exceptions. * Uncontrolled hypertension defined as blood pressure of ≥ 160 mmHg systolic and/or ≥ 95 mmHg diastolic. * Gross hemoptysis within 2 months of enrollment (defined as coughing up ≥ 0.5 teaspoons of fresh blood or small blood clots). * Concurrent use of therapeutic anticoagulation or anti-platelet agents. * H…